Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | CHAT | P28329 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 6/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 3/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26425332 | 0.89 | AHR (0.43) | RELAMAOB | |
| SCHEMBL26425331 | 0.85 | RELA (0.40) | RELAMAOBCYP1A2MAOANFE2L2 | |
| SCHEMBL26425329 | 0.84 | RELA (0.44) | RELAMAOBMAOAFBP1HRH4 | |
| SCHEMBL26425445 | 0.83 | PDE4B (0.50) | RELACHATMAOBCYP1A2CYP2C9 | |
| SCHEMBL26425326 | 0.83 | NFE2L2 (0.50) | RELAMAOBMAOAFBP1HRH4 | |
| SCHEMBL26425309 | 0.83 | CHAT (0.42) | CHATMAOBHRH4 | |
| SCHEMBL26425323 | 0.81 | RELA (0.54) | RELACYP1A2FBP1NFE2L2CHRM5 | |
| SCHEMBL26425307 | 0.80 | NFE2L2 (0.52) | MAOBMAOAFBP1HRH4NFE2L2 | |
| SCHEMBL26425338 | 0.80 | PDE4B (0.44) | MAOBMAOAFBP1HRH4 | |
| SCHEMBL26425319 | 0.80 | PDE4A (0.41) | RELACYP1A2CYP2C9NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129381-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | THE GEORGE WASHINGTON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129381-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | TP53, ANXA5, MCL1 | RELA 349/4885CHAT 3701/4885MAOB 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.